![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LHX1 |
Gene summary for LHX1 |
![]() |
Gene information | Species | Human | Gene symbol | LHX1 | Gene ID | 3975 |
Gene name | LIM homeobox 1 | |
Gene Alias | LIM-1 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P48742 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3975 | LHX1 | S014 | Human | Liver | HCC | 3.91e-17 | 8.71e-01 | 0.2254 |
3975 | LHX1 | S015 | Human | Liver | HCC | 1.17e-21 | 1.07e+00 | 0.2375 |
3975 | LHX1 | S016 | Human | Liver | HCC | 4.15e-40 | 1.28e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006056011 | Liver | HCC | developmental growth involved in morphogenesis | 124/7958 | 234/18723 | 7.37e-04 | 4.47e-03 | 124 |
GO:00016553 | Liver | HCC | urogenital system development | 170/7958 | 338/18723 | 2.15e-03 | 1.08e-02 | 170 |
GO:00018222 | Liver | HCC | kidney development | 148/7958 | 293/18723 | 3.25e-03 | 1.49e-02 | 148 |
GO:00720012 | Liver | HCC | renal system development | 152/7958 | 302/18723 | 3.45e-03 | 1.56e-02 | 152 |
GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
GO:00074921 | Liver | HCC | endoderm development | 43/7958 | 77/18723 | 1.24e-02 | 4.51e-02 | 43 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LHX1 | SNV | Missense_Mutation | novel | c.220N>T | p.Asp74Tyr | p.D74Y | P48742 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LHX1 | SNV | Missense_Mutation | novel | c.505N>T | p.Asn169Tyr | p.N169Y | P48742 | protein_coding | deleterious(0.01) | possibly_damaging(0.851) | TCGA-AC-A7VB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LHX1 | SNV | Missense_Mutation | novel | c.515N>T | p.Asp172Val | p.D172V | P48742 | protein_coding | deleterious(0.03) | possibly_damaging(0.776) | TCGA-GM-A5PV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LHX1 | insertion | Frame_Shift_Ins | rs775423572 | c.1187_1188insC | p.Glu399ArgfsTer65 | p.E399Rfs*65 | P48742 | protein_coding | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
LHX1 | SNV | Missense_Mutation | novel | c.614N>T | p.Pro205Leu | p.P205L | P48742 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LHX1 | SNV | Missense_Mutation | novel | c.457G>A | p.Ala153Thr | p.A153T | P48742 | protein_coding | tolerated(0.71) | benign(0.001) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LHX1 | SNV | Missense_Mutation | novel | c.628N>T | p.Arg210Cys | p.R210C | P48742 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
LHX1 | SNV | Missense_Mutation | rs773502109 | c.1190N>A | p.Pro397His | p.P397H | P48742 | protein_coding | deleterious(0) | possibly_damaging(0.554) | TCGA-CK-6748-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LHX1 | SNV | Missense_Mutation | novel | c.236C>T | p.Ala79Val | p.A79V | P48742 | protein_coding | tolerated(0.1) | probably_damaging(0.962) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
LHX1 | SNV | Missense_Mutation | novel | c.497C>T | p.Ala166Val | p.A166V | P48742 | protein_coding | tolerated(0.31) | benign(0.054) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |